Natural Immunity & Covid-19: Twenty-Nine Scientific Studies to Share with Employers, Health Officials, and Political figures
Sharing this lifesaving intel is essential with this information war!
From the beginning of the 03 2020 lockdowns for the SARS-CoV-2 virus, the subject of natural defenses (also called post-infection immunity) has been neglected.
Once the vaccination became widely available, what started with near silence at the beginning turned nearly into a complete blackout of the topic.
Even now, it comes with an absence of open discussion, presumably in the interests of advertising universal vaccination and needed documentation of such vaccination as a condition of taking part in public life and even the jobs marketplace. Still, the particular science exists. Many research exist. Their authors deserve credit, recognition, and to get their voices heard.
These studies demonstrate what was and is already known: natural immunity for a SARS-type virus is robust, long-lasting, and broadly effective during the case of mutations, usually more so than vaccines. Actually a major contribution of 20th-century science has been to increase upon and further elucidate this principle that has been known since the ancient world. Every professional presumably knew this a long time before the current debates. The effort to pretend otherwise is a technological scandal of the highest order, especially because the continued overlook of the topic is affecting the rights and freedoms of billions of people.
People who have contracted the virus and recovered deserve identification. For that matter, people who prefer an exposure risk to the virus in order to gain robust defenses deserve the freedom to make that choice. The realization that natural immunity – which pertains now to perhaps half of the US population and billions around the world – is effective in providing protection must have a dramatic effect on shot mandates.
Individuals whose livelihoods and liberties are being deprecated and erased need access to the medical literature as it pertains to this trojan. They should send a link to this page far and wide. The researchers have not been silent; they will just haven’t received the general public attention they deserve. The preparation of this list has been assisted by links provided by Paul Elias Alexander and Rational Ground’s own cheat sheet on natural immunity, which usually also includes links in order to popular articles on the topic.
1 . One-year continual cellular and humoral immunities of COVID-19 convalescents , by Jie Zhang, Hao Lin, Beiwei Ye, Min Zhao, Jianbo Zhan, et al. Clinical Infectious Illnesses, October 5, 2021. “ SARS-CoV-2-specific IgG antibodies, as well as NAb can persist amongst over 95% COVID-19 convalescents from 6 months to a year after disease onset. A minimum of 19/71 (26%) of COVID-19 convalescents (double positive within ELISA and MCLIA) experienced detectable circulating IgM antibody against SARS-CoV-2 at 12m post-disease onset. Notably, the percentages of convalescents along with positive SARS-CoV-2-specific T-cell reactions (at least one of the SARS-CoV-2 antigen S1, S2, M and N protein) had been 71/76 (93%) and 67/73 (92%) at 6m plus 12m, respectively. Furthermore, each antibody and T-cell storage levels of the convalescents were positively associated with their disease severity. ”
second . Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus success infections , by Sivan Gazit, Roei Shlezinger, Galit Perez, Roni Lotan, Asaf Peretz, Amir Ben-Tov, Dani Cohen, Khitam Muhsen, Gabriel Chodick, Tal Patalon. MedRxiv, August 25, 2021. “ Our analysis demonstrates that will SARS-CoV-2-naï ve vaccinees had a 13. 06-fold increased risk for breakthrough infection with all the Delta variant compared to individuals previously infected, when the 1st event (infection or vaccination) occurred during January and February of 2021. The particular increased risk was significant for a symptomatic disease as well…. This analysis proven that natural immunity offers longer lasting and stronger defense against infection, symptomatic disease and hospitalization due to the Delta variant of SARS-CoV-2, compared to the BNT162b2 two-dose vaccine-induced immunity. ”
a few. Shedding associated with Infectious SARS-CoV-2 Despite Vaccination , by Kasen E. Riemersma, Brittany E. Grogan, Amanda Kita-Yarbro, Gunnar Electronic. Jeppson, David H. O’Connor, Thomas C. Friedrich, Katarina M. Grande, MedRxiv, August 24, 2021. “ The SARS-CoV-2 Delta variant might cause high viral loads, is highly transmissible, and contains mutations that confer partial immune escape. Outbreak investigations suggest that vaccinated persons can spread Delta. We compared RT-PCR routine threshold (Ct) data from 699 swab specimens gathered in Wisconsin 29 06 through 31 July 2021 and tested with a qualitative assay by a single agreement laboratory. Specimens came from residents of 36 counties, the majority of in southern and southeastern Wisconsin, and 81% associated with cases were not associated with an outbreak. During this time, estimated frequency of Delta variants within Wisconsin increased from 69% to over 95%. Vaccination status was determined via self-reporting and state immunization information. ”
4. Necessity of COVID-19 vaccination in earlier infected individuals , by Nabin K. Shrestha, Patrick C. Burke, Amy S. Nowacki, Paul Terpeluk, Steven M. Gordon, MedRxiv, 06 5, 2021. “ People who have had SARS-CoV-2 infection are unlikely to benefit from COVID-19 vaccination, and vaccines could be safely prioritized to those who have not been infected prior to. ”
five. Large-scale study of antibody titer decay following BNT162b2 mRNA vaccine or SARS-CoV-2 infection , by Ariel Israel, Yotam Shenhar, Ilan Green, Eugene Merzon, Avivit Golan-Cohen, Alejandro A Schä ffer, Eytan Ruppin, Shlomo Vinker, Eli Magen. MedRxiv, August twenty two, 2021. “ This research demonstrates individuals who received the particular Pfizer-BioNTech mRNA vaccine have different kinetics of antibody levels compared to patients who was simply infected with the SARS-CoV-2 disease, with higher initial amounts but a much faster exponential decrease in the first group. ”
6. Discrete Immune Response Signature to SARS-CoV-2 mRNA Vaccination Versus Infection , by Ellie Ivanova, Paul Devlin, et al. Cell, May 2021. “ Whilst both infection and vaccination induced robust innate and adaptive immune responses, our analysis revealed significant qualitative differences between the two sorts of immune challenges. In COVID-19 patients, immune responses had been characterized by a highly augmented interferon response which was largely lacking in vaccine recipients. ”
7. SARS-CoV-2 irritation induces long-lived bone marrow plasma cells in people , by Jackson S i9000. Turner, Wooseob Kim, Elizaveta Kalaidina, Charles W. Goss, Adriana M. Rauseo, Aaron J. Schmitz, Lena Hansen, Alem Haile, Michael K. Klebert, Iskra Pusic, Anne A. O’Halloran, Rachel M. Presti, Ali H. Ellebedy. Nature, May 24, 2021. “ This study sought to determine whether infection with SARS-CoV-2 induces antigen-specific long-lived BMPCs in humans. We all detected SARS-CoV-2 S-specific BMPCs in bone marrow aspirates from 15 out of nineteen convalescent individuals, and in not one from the 11 control participants…. Overall, our results are consistent with SARS-CoV-2 infection eliciting a canonical T-cell-dependent B cellular response, in which an early transient burst of extrafollicular plasmablasts generates a wave associated with serum antibodies that decrease relatively quickly. This is then more stably maintained levels of serum antibodies that are supported by long-lived BMPCs. ”
8. Longitudinal analysis shows durable and broad defense memory after SARS-CoV-2 infections with persisting antibody reactions and memory B and T cells , simply by Kristen W. Cohen, Susanne L. Linderman, Zoe Moodie, Julie Czartoski, Lilin Lai, Grace Mantus, Carson Norwood, Lindsay E. Nyhoff, Venkata Viswanadh Edara, et ing. MedRxiv, April 27, 2021. “ Ending the COVID-19 pandemic will require long-lived defenses to SARS-CoV-2. We examined 254 COVID-19 patients longitudinally from early infection as well as for eight months thereafter and found a predominant broad-based immune memory response. SARS-CoV-2 spike binding and normalizing antibodies exhibited a bi-phasic decay with an extended half-life of > 200 times suggesting the generation associated with longer-lived plasma cells. In addition , there was a sustained IgG+ memory B cell response, which bodes well for the rapid antibody response upon virus re-exposure. ”
9. Incidence of Severe Severe Respiratory Syndrome Coronavirus-2 infection among previously infected or even vaccinated employees , simply by N Kojima, A Roshani, M Brobeck, A Lihat, JD Klausner. MedRxiv, This summer 8, 2021. “ Prior SARS-CoV-2 infection and vaccination for SARS-CoV-2 were associated with decreased risk for contamination or re-infection with SARS-CoV-2 in a routinely screened labor force. The was no distinction in the infection incidence between vaccinated individuals and people with previous infection. Further research is needed to determine whether our answers are consistent with the emergence of new SARS-CoV-2 variants. ”
10. Single cell profiling of T and B cellular repertoires following SARS-CoV-2 mRNA vaccine , by Suhas Sureshchandra, Sloan A. Lewis, Brianna Doratt, Allen Jankeel, Izabela Ibraim, Ilhem Messaoudi. BioRxiv, July 15, 2021. “ Interestingly, clonally expanded CD8 T cells had been observed in every vaccinee, because observed following natural disease. TCR gene usage, however , was variable, reflecting the diversity of repertoires and MHC polymorphism in the human population. Natural infection induced development of larger CD8 Big t cell clones occupied distinct clusters, likely due to the recognition of a broader set of virus-like epitopes presented by the disease not seen in the mRNA vaccine. Our study shows a coordinated adaptive immune system response where early CD4 T cell responses facilitate the development of the B cell response and substantial growth of effector CD8 Capital t cells, together capable of adding to future recall responses. ”
11. mRNA vaccine-induced Big t cells respond identically in order to SARS-CoV-2 variants of concern but differ in longevity and homing properties depending on previous infection status , Jason Neidleman, Xiaoyu Luo, Matt McGregor, Guorui Xie, Victoria Murray, Warner C. Greene, Sulggi A. Lee, Nadia R. Roan. BioRxiv, This summer 29, 2021. “ Within infection-naï ve individuals, the second dose boosted the quantity and altered the phenotypic attributes of SARS-CoV-2-specific T tissues, while in convalescents the second dosage changed neither. Spike-specific T cells from convalescent vaccinees differed strikingly from those of infection-naï ve vaccinees, with phenotypic features suggesting excellent long-term persistence and ability to home to the respiratory tract including the nasopharynx. These results provide reassurance that vaccine-elicited T cells respond robustly in order to emerging viral variants, make sure convalescents may not need a second vaccine dose, and claim that vaccinated convalescents may have more persistent nasopharynx-homing SARS-CoV-2-specific Capital t cells compared to their infection-naï ve counterparts. ”
12. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection , Jennifer M. Dan, Jose Mateus, Yu Kato, Kathryn Mirielle. Hastie, et al., Technology, January 6, 2021. “ Understanding immune memory in order to SARS-CoV-2 is critical for improving diagnostics and vaccines, and for assessing the likely long term course of the COVID-19 outbreak. We analyzed multiple compartments of circulating immune storage to SARS-CoV-2 in 254 samples from 188 COVID-19 cases, including 43 samples at ≥ 6 months post-infection. IgG to the Spike proteins was relatively stable more than 6+ months. Spike-specific storage B cells were a lot more abundant at 6 months compared to at 1 month post indicator onset. SARS-CoV-2-specific CD4+ T cells and CD8+ To cells declined with a half-life of 3-5 months. Simply by studying antibody, memory W cell, CD4+ T cellular, and CD8+ T cell memory to SARS-CoV-2 in an integrated manner, we noticed that each component of SARS-CoV-2 defense memory exhibited distinct kinetics. ”
13. Persistence associated with neutralizing antibodies a year after SARS-CoV-2 infection , by Anu Haveri, Nina Ekströ m, Anna Solastie, Camilla Virta, Pamela Ö sterlund, Elina Isosaari, Hanna Nohynek, Arto A. Palmu, Value Melin. MedRxiv, July 16, 2021. “ We assessed the persistence of serum antibodies following wild-type SARS-CoV-2 infection six and 12 months after diagnosis in 367 individuals of whom 13% had severe disease needing hospitalization. We determined the SARS-CoV-2 spike (S-IgG) plus nucleoprotein IgG concentrations as well as the proportion of subjects along with neutralizing antibodies (NAb). ”
14. Quantifying the risk of SARS‐ CoV‐ 2 reinfection as time passes , by Eamon U Murchu, Paula Byrne, Paul G. Carty, et ‘s. Rev Med Virol. 2021. “ Reinfection was an uncommon event (absolute rate 0%– 1 . 1%), without study reporting an increase within the risk of reinfection with time. Only one study esti- combined the population‐ level risk of reinfection based on whole genome sequencing in a subset of patients; the approximated risk was low (0. 1% [95% CI: 0.08–0.11%]) with no evidence of waning immunity for up to 7 months following primary infection. These data suggest that naturally acquired SARS‐ CoV‐ 2 immunity does not wane for at least ten months post‐ infection. However , the applicability of these research to new variants or to vaccine‐ induced immunity continues to be uncertain. ”
15. SARS-CoV-2 antibody-positivity protects against reinfection for at least seven weeks with 95% efficacy , by Laith J. Abu-Raddad, Hiam Chemaitelly, Peter Coyle, Joel A. Malek. The particular Lancet, July 27, 2021. “ Reinfection is rare in the young and worldwide population of Qatar. Natural infection appears to elicit strong protection against reinfection by having an efficacy ~95% for at least seven months. ”
16. Natural immunity against COVID-19 significantly reduces the risk of reinfection: findings from a cohort associated with sero-survey participants , by Bijaya Kumar Mishra, Debdutta Bhattacharya, Jaya Singh Kshatri, Sanghamitra Pati. MedRxiv, July 19, 2021. “ These types of findings reinforce the strong plausibility that development of antibody following natural infection not just protects against re-infection by the virus to a great extent, but also safeguards against progression to serious COVID-19 disease. ”
17. Protection of previous SARS-CoV-2 infection is similar to that of BNT162b2 vaccine protection: A three-month nationwide experience from His home country of israel , by Yair Goldberg, Micha Mandel, Yonatan Woodbridge, Ronen Fluss, Ilya Novikov, Rami Yaari, Arnona Ziv, Laurence Freedman, Amit Huppert, et al.. MedRxiv, April 24, 2021. “ Likewise, the overall estimated level of protection from prior SARS-CoV-2 infection regarding documented infection is 94· 8% (CI:[94·4, 95·1]); hospitalization 94· 1% (CI:[91·9, 95·7]); and serious illness 96· 4% (CI:[92·5, 98·3]). Our outcomes question the need to vaccinate previously-infected individuals. ”
18. Defense Memory in Mild COVID-19 Patients and Unexposed Contributor Reveals Persistent T Cellular Responses After SARS-CoV-2 Infections , by Asgar Ansari, Rakesh Arya, Shilpa Sachan, Someshwar Nath Jha, Anurag Kalia, Anupam Lall, Alessandro Sette, et al. Front Immunol. March 11, 2021. “ Using HLA class II predicted peptide megapools, we identified SARS-CoV-2 cross-reactive CD4+ T cells in around 66% of the unexposed individuals. Moreover, we discovered detectable immune memory in mild COVID-19 patients several months after recovery in the crucial arms of protective adaptive immunity; CD4+ T tissue and B cells, using a minimal contribution from CD8+ T cells. Interestingly, the particular persistent immune memory in COVID-19 patients is predominantly targeted towards the Spike glycoprotein of the SARS-CoV-2. This study provides the evidence of both high magnitude pre-existing and persistent immune memory in Indian population. ”
19. Live virus neutralisation testing in convalescent patients and topics vaccinated against 19A, 20B, 20I/501Y. V1 and 20H/501Y. V2 isolates of SARS-CoV-2 , by Claudia Gonzalez, Carla Saade, Antonin Bal, Martine Valette, et ing, MedRxiv, May 11, 2021. “ No significant difference was observed between the 20B and 19A isolates for HCWs with mild COVID-19 plus critical patients. However , a substantial decrease in neutralisation ability has been found for 20I/501Y. V1 in comparison with 19A isolate intended for critical patients and HCWs 6-months post infection. Regarding 20H/501Y. V2, all populations had a significant reduction in neutralising antibody titres in comparison with the 19A isolate. Interestingly, a substantial difference in neutralisation capacity was observed for vaccinated HCWs between the two variants whereas it was not substantial for the convalescent groups. ”
20. Highly functional virus-specific cellular immune response in asymptomatic SARS-CoV-2 infection , by Nina Le Bert, Hannah E. Clapham, Anthony T. Tan, Wan National insurance Chia, et al, Log of Experimental Medicine, March 1, 2021. “ Hence, asymptomatic SARS-CoV-2– infected individuals are not characterized by weak antiviral immunity; on the contrary, they mount a highly functional virus-specific cellular immune response. ”
21. SARS-CoV-2-specific T cell storage is sustained in COVID-19 convalescent patients for 10 months with successful development of stem cell-like memory To cells , Jae Hyung Jung, Min-Seok Rha, Moa Sa, Hee Kyoung Choi, Ji Hoon Jeon, ou al, Nature Communications, 06 30, 2021. “ Specifically, we observe sustained polyfunctionality and proliferation capacity associated with SARS-CoV-2-specific T cells. Among SARS-CoV-2-specific CD4+ and CD8+ T cells detected simply by activation-induced markers, the percentage of stem cell-like memory T (TSCM) cells is definitely increased, peaking at approximately 120 DPSO. Development of TSCM cells is confirmed by SARS-CoV-2-specific MHC-I multimer staining. Considering the self-renewal capacity and multipotency of TSCM cellular material, our data suggest that SARS-CoV-2-specific T cells are durable after recovery from COVID-19, thus support the feasibility of effective vaccination programs as a measure for COVID-19 control. ”
22. Antibody Evolution after SARS-CoV-2 mRNA Vaccination , by Alice Cho, Frauke Muecksch, Dennis Schaefer-Babajew, Zijun Wang, ainsi que al, BioRxiv, et ‘s, BioRxiv, July 29, 2021. “ We conclude that will memory antibodies selected as time passes by natural infection possess greater potency and breadth than antibodies elicited simply by vaccination. These results suggest that boosting vaccinated individuals with currently available mRNA vaccines would create a quantitative increase in plasma neutralizing activity but not the qualitative advantage against variants attained by vaccinating convalescent people. ” More recent version says: “ These results claim that boosting vaccinated individuals with now available mRNA vaccines will increase lcd neutralizing activity but might not produce antibodies with width equivalent to those obtained simply by vaccinating convalescent individuals. ”
twenty three. Differential associated with the second SARS-CoV-2 mRNA vaccine dose on T cell immunity in naï ve and COVID-19 recovered people , by Carmen Camara, Daniel Lozano-Ojalvo, Eduardo Lopez-Granados. Et al., BioRxiv, March 27, 2021. “ Whilst a two-dose immunization routine with the BNT162b2 vaccine continues to be demonstrated to provide a 95% effectiveness in naï ve individuals, the effects of the second vaccine dose in individuals who have previously recovered from natural SARS-CoV-2 infection has been questioned. Right here we characterized SARS-CoV-2 spike-specific humoral and cellular defenses in naï ve plus previously infected individuals during full BNT162b2 vaccination. The results demonstrate that the second dose increases both the humoral and cellular immunity in naï ve individuals. On the other hand, the second BNT162b2 vaccine dosage results in a reduction associated with cellular immunity in COVID-19 recovered individuals, which suggests that a second dose, according to the present standard regimen of vaccination, may be not necessary in individuals previously infected with SARS-CoV-2. ”
twenty-four. COVID-19 organic immunity: Scientific Brief . World Health Organization. Might 10, 2021. “ Obtainable scientific data suggests that in many people immune responses stay robust and protective against reinfection for at least 6-8 months after infection (the longest follow up with strong scientific evidence is currently approximately 7 months). Some variant SARS-CoV-2 viruses with key changes in the spike protein have a reduced susceptibility to neutralization by antibodies in the blood. Whilst neutralizing antibodies mainly target the spike protein, mobile immunity elicited by natural infection also target various other viral proteins, which tend to be conserved across variants than the spike protein. ”
25. SARS-CoV-2 re-infection risk in Austria , by Stefan Pilz, Ali Chakeri, Mark Pa Ioannidis, et ‘s. Eur J Clin Commit. April 2021. “ We all recorded 40 tentative re-infections in 14 840 COVID-19 survivors of the first wave (0. 27%) and 253 581 infections in 6 885 640 individuals from the remaining general population (2. 85%) translating into a good odds ratio (95% confidence interval) of 0. 09 (0. 07 to 0. 13). We observed a relatively low re-infection rate associated with SARS-CoV-2 in Austria. Safety against SARS-CoV-2 after natural infection is comparable with the greatest available estimates on vaccine efficacies. Further well-designed analysis on this issue is urgently needed for improving evidence-based decisions on public health procedures and vaccination strategies. ”
26. Anti-spike antibody response to natural SARS-CoV-2 infection in the general population , simply by Jia Wei, Philippa C. Matthews, Nicole Stoesser, et al, MedRxiv, July 5, 2021. “ We estimated antibody amounts associated with protection against reinfection likely last 1 . 5-2 years on average, with ranges associated with protection from severe disease present for several years. These estimates could inform planning for vaccination booster strategies. ”
27. SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN ), by Victoria Jane Hall, FFPH, Sarah Foulkes, MSc, Andre Charlett, PhD, Ana Atti, MSc, et al. The Lancet, April 29, 2021. “ A previous history of SARS-CoV-2 infection was associated with an 84% lower risk of infection, with median defensive effect observed 7 a few months following primary infection. This time period is the minimum possible effect because seroconversions are not included. This study shows that previous infection with SARS-CoV-2 induces effective immunity to future infections in most people. ”
28. SARS-CoV-2 Natural Antibody Response Persists intended for at Least 12 Months in a Countrywide Study From the Faroe Island destinations , by Maria Skaalum Petersen, Cecilie Bo Hansen, Marnar Frí heim Kristiansen, et al, Open Forum Infectious Diseases, Volume 6, Issue 8, August 2021. “ Although the protective part of antibodies is currently not known, our results show that SARS-CoV-2 antibodies persisted a minimum of 12 months after symptom starting point and maybe even longer, demonstrating that COVID-19-convalescent individuals may be shielded from reinfection. Our outcomes represent SARS-CoV-2 antibody immunity in nationwide cohorts in a setting with few undiscovered cases, and we believe that our results add to the understanding of organic immunity and the expected sturdiness of SARS-CoV-2 vaccine immune responses. Moreover, they can assist with public health policy and ongoing strategies for vaccine delivery.
29. Associations of Vaccination and of Prior Infection With Positive PCR Test Results for SARS-CoV-2 in Air travel Passengers Arriving in Qatar , by Roberto Bertollini, MD, MPH one ; Hiam Chemaitelly, MSc 2 ; Hadi M. Yassine. JAMA Analysis Letter, June 9, 2021. “ Of 9180 people with no record of vaccination but with a record of prior infection at least 90 days before the PCR test (group 3), 7694 could be matched to people with no record of vaccination or prior infection (group 2), among whom PCR positivity was 1 . 01% (95% CI, 0. 80%-1. 26%) and 3. 81% (95% CI, 3. 39%-4. 26%), respectively. The relatives risk for PCR positivity was 0. 22 (95% CI, 0. 17-0. 28) for vaccinated individuals and 0. 26 (95% CI, 0. 21-0. 34) for people with prior infection compared to no record of vaccination or prior infection. ”
Content articles in the popular media
Precisely why COVID-19 Vaccines Should Not Be Required for All Americans , by Marty Makary, US News, August 21, 2021
Having SARS-CoV-2 once confers much greater immunity than a vaccine— yet vaccination remains vital , by Meredith Wadson, Science, August 26, 2021
Natural disease vs vaccination: Which gives more protection? By David Rosenberg, Israeli Nationwide News, July 13, 2021.
Flu survivors still immune system after 90 years , by Ed Yong, National Geographic, August 17, 08.
Rescind Vaccine Mandates: Open up Letter to Medical Societies, Hospitals, Clinics, and Other Health care Facilities , Association associated with American Physicians and Surgeons, August 31, 2021.
University Vaccine Mandates Violate Medical Ethics , By Aaron Kheriaty and Gerard Sixth is v. Bradley, Wall Street Journal, June fourteen, 2021.
Immunity to the Coronavirus May Last Years, Brand new Data Hint , simply by Apoorva Mandavilli, New York Occasions, November 17, 2020.
The entire world Health Organization Oversold the particular Vaccine and Deprecated Organic Immunity , by Jeffrey Tucker, Brownstone Institute, Aug 29, 2021.
Why Does the particular CDC Recognize Natural Immunity for Chicken Pox however, not Covid? Simply by Paul Elias Alexander, Brownstone Institute, September 17, 2021.
Rand Paul and Xavier Becerra Square Off on Natural Immunity, with Destructive Results , by Brownstone Institute, October 2, 2021.
Lockdowns, Mandates, and Natural Immunity: Kulldorff vs . Offit , by Brownstone Institute, October 6, 2021.
Hospitals Should Hire, Not Fire, Nurses with Natural Immunity , by Martin Kulldorff, October 1, 2021.
The particular Strange Neglect of Organic Immunity , by Jayanta Bhattacharya, Brownstone Institute, This summer 28, 2021.